Paclitaxel-loaded nanoparticles decorated with bivalent fragment HAb18 F(ab’)₂ and cell penetrating peptide for improved therapeutic effect on hepatocellular carcinoma

Q2 · ENGINEERING & TECHNOLOGY

ArticleOA

Author: Bai, Ling ; Wang, Shuangquan ; Yin, Xiaolong ; Lin, Lemin ; Jin, Cheng

Hepatocellular carcinoma (HCC) shows low response to most conventional treatment strategies. Therefore, there is an urgent need for new and effective chemotherapies. Nanotechnology gives a dramatic impact on medicine. In this work, paclitaxel loaded nanoparticles (NPs) decorated with bivalent fragment HAb18 F(ab')₂ and/or cell penetrating peptide (CPP) were developed and evaluated. NPs were prepared by emulsification-solvent evaporation method and decorated by carbodiimide chemistry. The physicochemical characteristics of NPs (i.e. encapsulation efficiency, particle size distribution, morphology, release in vitro) were investigated. Cellular uptake and accumulation in tumor tissue of NPs were determined. To assess anti-tumor activity of NPs in vitro and in vivo, cell survival assay and tumor regression study were carried out using HCC cell lines (HepG2 and Huh7) and their xenografts. Average particle size of all NPs was between 100 and 200 nm. Drug-loaded NPs possessed spherical morphology and higher encapsulation efficiency. The accumulation of NPs decorated with HAb18 F(ab')₂ and CPP depended on dual effects of passive and active targeting. Drug loaded nanoparticles showed cytotoxicity on the tumor cells in vitro and in vivo. NPs decorated with HAb18 F(ab')₂ and CPP showed maximization of therapeutic action for targeting and effective endocytosis. These results suggest that the nano-drug delivery system could be a promising candidate with excellent therapeutic efficacy for HCC therapy.

01 Nov 2011·Journal of Controlled ReleaseQ1 · MEDICINE

Preparation and characterization of targeted DOX–PLGA–PEG micelles decorated with bivalent fragment HAb18 F(ab′) 2 for treatment of hepatocellular carcinoma

Q1 · MEDICINE

Article

Author: Wang, Junqing ; Dou, Kefeng ; Jin, Cheng ; Bai, Ling ; Yang, Wenqing

Characteristics and cytotoxicity of targeted doxorubicin-poly(lactic-co-glycolic acid)-poly(ethylene glycol) (DOX-PLGA-PEG) micelles decorated with the bivalent fragment HAb18 F(ab')₂ for hepatocellular carcinoma (HCC) were studied.The micelles had a satisfactory morphol. and high loading efficiency.Cellular uptake and accumulation in tumor was observedThe accumulation of targeted micelles depends on dual effects of passive and active targeting.The drug-loaded micelles showed cytotoxicity on tumor cells in vitro and in vivo.Application of the targeted micelles resulted in significant improvement in therapeutic response.

13 Sep 2010·BiomacromoleculesQ2 · CHEMISTRY

Improved Therapeutic Effect of DOX-PLGA-PEG Micelles Decorated with Bivalent Fragment HAb18 F(ab′)₂ for Hepatocellular Carcinoma

Q2 · CHEMISTRY

Article

Author: Dou, Kefeng ; Song, Wenjie ; Jin, Cheng ; Yang, Wenqing ; Bai, Ling ; Wang, Minchang ; Wu, Hong ; Qian, Niansong ; Zhao, Wei

Although surgery offers the only hope of cure for hepatocellular carcinoma (HCC), patients with inoperable or metastatic disease have a dismal prognosis. Therefore, there is an urgent need for new and effective treatment strategies. Polymeric micelles composed of drug conjugated to a diblock copolymer have attracted great interest for clinical administration of anticancer drugs. In this work, characteristics and cytotoxicity of doxorubicin-poly(d,l-lactic-co-glycolic acid)-poly(ethylene glycol) (DOX-PLGA-PEG) micelle and its targeted micelle decorated with bivalent fragment HAb18 F(ab')(2) for HCC were studied. These micelles possessed spherical morphology and higher loading efficiency. Cellular uptake and accumulation in tumor tissue of micelles was observed. The accumulation of the targeted micelles depends on dual effects of passive and active targeting. The drug-loading micelles showed cytotoxicity on tumor cells in vitro and in vivo. The targeted micelles resulted in significant improvement in therapeutic response. These results suggest that the novel micelles could be a promising candidate with excellent therapeutic efficacy for targeting the drugs to cancer cells.

100 Deals associated with Equine anti-Tetanus F(ab')2(Shanghai Serum Biotechnology )

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Tetanus	CN	Shanghai Serum Bio-Technology Co., Ltd.	01 Jan 1982

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Equine anti-Tetanus F(ab')2(Shanghai Serum Biotechnology )

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation